|
|
Phase II Study of Sulindac And Epirubicin Hydrochloride in Patients With Metastatic Malignant Melanoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
ICORG-06-03 ICORG 06-03 Epi Sulindac, EUDRACT-2006-006051-12, EU-20876, NCT00755976
|
|
|
Objectives Primary - To estimate the non-comparative efficacy of sulindac and epirubicin hydrochloride in patients with metastatic malignant melanoma.
Secondary - To characterize the toxicity of this regimen in these patients.
Entry Criteria Disease Characteristics:
- Histologically confirmed malignant melanoma
- Tumor block available for resistance marker analysis
- Measurable or evaluable disease
- No active brain metastases except for patients who have undergone successful complete excision of solitary brain metastasis
Prior/Concurrent Therapy:
- No prior anthracycline or anthracenedione-containing chemotherapy regimen
- No prior cardiac radiotherapy
- No major surgery within the past 2 weeks
- No participation in any clinical trial within the past 4 weeks
- No other concurrent anticancer therapies
- Concurrent bisphosphonates allowed in patients with bony metastases with extra-osseous measurable or evaluable lesions
- No other concurrent experimental medications
Patient Characteristics:
- Karnofsky performance status 80-100%
- ANC > 1 x 109/L
- Platelet count > 100 x 109/L
- Hemoglobin > 9 g/dL
- Serum bilirubin normal (except in patients with benign congenital hyperbilirubinemia)
- Not pregnant or nursing
- Negative pregnancy test
- Normal cardiac ejection fraction, cardiac wall motion, and ECG
- No active heart disease, including any of the following:
- Myocardial infarction within the past year
- Pericarditis
- Existing hypertension requiring treatment
- No other active serious medical or psychiatric disease
- No prior or concurrent malignancy, other than basal cell carcinoma of the skin , or carcinoma in-situ of the cervix
Expected Enrollment 38Outcomes Primary Outcome(s)Non-comparative efficacy
Secondary Outcome(s)Toxicity according to NCI CTCAE v.3.0
Outline This is a multicenter study. Patients receive oral sulindac 2 hours prior to receiving epirubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Previously collected tumor blocks are assessed for cancer resistance markers by IHC. After completion of study treatment, patients are followed for 1 month, and then every 3 months thereafter.
Trial Contact Information
Trial Lead Organizations Irish Clinical Oncology Research Group | | | John Crown, MD, Principal investigator | | | | Trial Sites
|
|
|
|
Ireland |
|
|
Cork |
|
| | | Cork University Hospital |
| | Seamus O'Reilly, MD, BSc, PhD | |
|
|
Dublin |
|
| | Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital |
| | Ray McDermott, MD | |
| Email:
ray.mcdermott@amnch.ie |
| | Beaumont Hospital |
| | Oscar Breathnach, MD | |
| | Mater Misericordiae University Hospital |
| | John McCaffrey, MD | |
| | National Institute for Cellular Biotechnology at Dublin City University |
| | Robert O'Connor, MD | |
| Email:
robert.oconnor@dcu.ie |
| | St. James's Hospital |
| | M. John Kennedy, MD | |
| Email:
jkennedy@stjames.ie |
| | St. Vincent's University Hospital |
| | John Crown, MD | |
|
|
Galway |
|
| | Galway University Hospital |
| | Maccon Keane, MD | |
| Email:
maccon.keane@mailn.hse.ie |
|
|
Limerick |
|
| | Mid-Western Cancer Centre at Mid-Western Regional Hospital |
| | Rajnish Gupta, MD | |
|
|
Waterford |
|
| | Waterford Regional Hospital |
| | Paula Calvert, MD | |
|
Registry Information | | Official Title | | Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma | | Trial Start Date | | 2007-08-01 | | Trial Completion Date | | 2009-08-31 (estimated) | | Registered in ClinicalTrials.gov | | NCT00755976 | | Date Submitted to PDQ | | 2008-08-29 | | Information Last Verified | | 2008-09-23 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|